Form 4: Nuvectis Pharma Director Increases Indirect Holdings Through Emerald Hill Ventures

Charles Mosseri Marlio, a director of Nuvectis Pharma, indirectly increased his holdings through purchases made by Emerald Hill Ventures SARL SPF between May 6th and May 8th, 2025.

Summary

• Charles Mosseri Marlio, a director of Nuvectis Pharma, has reported changes in his beneficial ownership of the company's common stock.
• The transactions occurred between May 6th and May 8th, 2025.
• The shares were acquired indirectly through Emerald Hill Ventures SARL SPF, of which Mr. Mosseri Marlio is the beneficial owner.
• The purchases were made at prices ranging from $8.40 to $8.65 per share.
• A total of 27,357 shares were purchased across multiple transactions.
• Following these transactions, Mr. Mosseri Marlio indirectly owns 2,911,532 shares through Emerald Hill Ventures SARL SPF.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine insider trading activity, which doesn't inherently indicate positive or negative sentiment, but the purchases could be seen as a slightly positive signal.

Positives

• The director's increased investment could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders.

Stakeholder Impact

• The increased holdings by a director could be viewed positively by shareholders.

Key Dates

Keywords

Nuvectis Pharma, Charles Mosseri Marlio, Emerald Hill Ventures, Beneficial Ownership, Form 4, Director, NVCT, Stock Purchase